Co‐trimoxazole prophylaxis has been shown to be associated with lower morbidity and mortality in patients with higher CD4 cell counts in Sub‐Saharan Africa, mainly due to its effectiveness in preventing infections other than PjP [34, 35]. This evidence concerns the gene CD4 and infection.